ALLO Allogene Therapeutics Inc

$ALLO Nice plug from Fox Business News! There guest on Making Money just had a large shoutout for ALLO. Stocks is not reacting, but he was very high on there technology! You don't see Analyst recommending $2 stocks very often!

$ALLO Fear and loathing for weeks. Yet, we may be on the precipice of seeing beauty for ashes, dancing for mourning, strength for fear. Ultimately, let's get a good product out there that may help a lot of people in their fight against cancer.

$ALLO Finally trading under cash again. Gonna start increasing my position. Same as the last time this happened

$ALLO The more you look at this exceptional SSc patient from the ALLO-329 RESOLUTION trial abstract 1178 from ACR Convergence 2026, the more important the result becomes. This was progressive, treatment-refractory diffuse systemic sclerosis - a serious, high-mortality autoimmune disease - yet at only 40M ALLO-329 cells + cyclophosphamide, her mRSS dropped from 19 to 6 in just 3 months. Every time you put this patient into the proper disease context, the result tells us something important. It is still early and we need more patients and follow-up, but a 13-point reduction in clinically assessed skin thickness in progressive dcSSc deserves attention. This is one of the hardest autoimmune diseases to treat. This graphic below puts that result into perspective.

$ALLO if 329 is positive then we go to 75. It could be a bargain of the century at 1.60. Keep moving down so I can buy more! With others failing Allo technology could be te real deal. With no ichans or CRS the big boys could be knocking on their doors if trials succeed!

$ALLO Majority of market down, not just allo. I knew after the USA rate hike, small cap and non revenue companies will get hit..does it make sense? No, cause allo has no debt...market manipulation at its finest...so hedges can make millions. But its part if the game..

$ALLO Holy F$&$ this really went green on Friday? Breaks a string of 12 straight days red. Did 10M in volume. Hmm

$ALLO Will the LBAs publish on Monday? Last year the late breaking abstracts published at what would be next week on Monday. They published on Monday October 13th. If Allogene has a late breaking abstract it could show up as early as next week. Also, if an LBA actually does show up from Allogene next week, it would fit in with the silence. Have a great weekend Longs.

$ALLO ALLO-329, Autoimmune, Immune reset, No Chemo. Major disruption took place in the first 14 days in the exceptional SSc patient discussed in abstract 1178. The image below shows this disruption and then the values keep going down as time moves forward. Remember if those bad T helper cells have been dismantled, it will take about six months for that network to come back. That network should come back to a balanced system and be healthy. Note: If this was a CD19 only CAR-T therapy, persistence is required because the T-helper network gets starved out by the B cells being suppressed. ALLO-329 targets them immediately when infused into the body.

$ALLO just posted fullninterview on fox, high expectations for ALLO towards the end of this year.

$ALLO Technical selling from the recent Caribou panic has pushed the stock against book value floor, but the actual underlying data points to a massive disconnect ahead of the ACR Convergence conference on Nov 9. The preliminary Phase 1 RESOLUTION data for the ALLO-329 autoimmune platform is already live and fully verified on the official ACR medical abstract registry (Abstract #1178): • Safety Blueprint: 0% Dose-Limiting Toxicities (DLTs) across the initial 9 patients treated. • Mechanism Proof: Successful B-cell depletion was explicitly achieved in both lymphodepleted and completely non-lymphodepleted (chemo-free) cohorts via their Dagger® tech [1.21]. • Early Clinical Efficacy: A severe Scleroderma patient saw a massive mRSS skin thickness reduction from 19 at baseline down to 6 at Month

$ALLO 🔥 ALLO-329 ACR abstract is now public and the early data are VERY encouraging • 9 patients treated • No DLTs • Only 1 Grade-1 CRS • B-cell suppression demonstrated • Activity at low doses • Activity even without conventional cyclophosphamide lymphodepletion 🔥 Standout result: systemic-sclerosis patient mRSS 19 → 6 at Month 3. Several individual areas reached 0, including upper arm by Day 14 and foot by Day 28. This could be a major validation signal for Allogene’s Dagger platform and the potential for off-the-shelf CAR-T with reduced/no traditional lymphodepletion. 📅 ALLO-329 ACR pres: Nov 9 🔥 TPG overhang is also GONE. TPG sold its entire 18.7M-share position at $1.55 (~$29M). Zero shares remaining. Meanwhile, ALLO has ~$424M cash/investments and runway into Q1 2029. So we have: ✅ ALLO-329 clinical activity ✅ Clean safety so far ✅ Dagger differentiation ✅ Huge cash runway ✅ TPG selling pressure finished ✅ November catalyst ✅ ALPHA3 ahead ✅ Significant short interest

$ALLO for ALLO to be mentioned on FOX business I believe something is brewing. I bought more this morning I’ll keep adding in case it keep dropping

$ALLO Kevin Mahn was on the Schwab Network shilling for #ALLO again today. What's with this guy? Interview was on LinkedIn and ALLO liked it.... Hmmm

$ALLO On August 11, 2026, I posted that instructional holding stood at 61%. As of today, it has risen to 84.22%. Something for shorting enthusiasts to consider!

$ALLO Likely, it will slowly (and painfully) grind its way up to 2.0 before the next cycle of shorting starts; or, sky rocket based on the November announcement. Let’s see.

$ALLO If you want to see how to properly do a an offering after "good data, see #VSTM this morning. They did an offering above last night's closing price after really good data was released. This is unlike what these fools did. Who does an offering at $2 when the stock is trading at $4 per share??? Idiots

$ALLO According to their Q2 2026 financial reports and subsequent business presentations, the company remains on track to provide a clinical and translational update for its pivotal Phase 2 ALPHA3 program. This trial evaluates their lead candidate, cemacabtagene ansegedleucel (cema-cel), as a first-line consolidation therapy for minimal residual disease (MRD)-guided Large B-Cell Lymphoma (LBCL). Furthermore, during recent biopharma conferences, management indicated they plan to release initial clinical data from their Phase 1 autoimmune disease program evaluating ALLO-329 (the RESOLUTION trial) at an upcoming medical conference later this yea

$ALLO super low volume....good place to add if it gets back to 1.26-1.29 and trading below book again.

$ALLO Have you ever thought that cema is the only real asset left in the pipeline? If the results next June aren’t good it’s bye-bye and hello bankruptcy.